JCO

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

JCO
Mar 18, 2025, 16:54 | Positive
The launch of the official JCO Journals LinkedIn page
JCO Journals shared a post on LinkedIn: "We're thrilled to announce the launch of the…
Feb 3, 2025, 14:40 | Blog
Paolo Tarantino: Fixed dose of capecitabine vs standard dose for Metastatic Breast Cancer
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper…
Feb 3, 2025, 14:01 | Blog
Vivek Subbiah: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on…
Jan 25, 2025, 16:19 | Science
Paolo Tarantino: Evolutions in the treatment of HER2+ breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Tess A. O'Meara…
Dec 27, 2024, 08:06 | Science
The Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs - JCO Oncology Practice
JCO Oncology Practice shared an article by Vanessa Mara Samuel on X: "Evaluating the Economic…
Dec 23, 2024, 12:23 | Science
Paolo Tarantino: PostMONARCH is out in Journal of Clinical Oncology
A recent paper by Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship,…
Dec 22, 2024, 15:33 | Oncolibrary
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
New Paper Published in JCO Oncology Practice on Dec 17, 2024 on HR+ Breast Cancer…
Dec 19, 2024, 11:54 | Opinion
Lung Cancer Trial Highlights from 2024 By Yakup Ergün
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X: “What happened in Lung…
Nov 18, 2024, 12:54 | Insight
Ovarian Function Suppression in Premenopausal Women With Breast Cancer
Dario Trapani, Medical oncologist at the European Institute of Oncology (IEO), shared a post by…
Oct 26, 2024, 10:44 | Blog
Laura Vater: JCO podcast about grief and the power of colleagues who support one another
Laura Vater, Gastrointestinal oncologist at the IU Simon Comprehensive Cancer Center, shared a post on…
Oct 25, 2024, 14:25 | Insight
Aaron Mitchell: New findings on cancer care quality for low-income Medicare patients
Aaron Mitchell, Medical Oncologist and Health Services Researcher at Memorial Sloan Kettering Cancer Center, shared…
Oct 18, 2024, 16:33 | Blog
Jonathan Friedberg: End Point Surrogacy in First-Line CLL
Jonathan Friedberg, Director of Wilmot Cancer Institute, posted the following on X: “End Point Surrogacy in…
Oct 15, 2024, 16:40 | Insight
First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma - Journal of Clinical Oncology
Journal of Clinical Oncology shared a post on X: "Survival Outcomes Associated With First-Line Procarbazine, CCNU,…
Oct 13, 2024, 22:27 | Insight
Stephen Liu: Analysis of locoregional relapse after segmentectomy in JCOG0802
Stephen Liu shared a post on X: “Analysis of locoregional relapse after segmentectomy in JCOG0802.…
Oct 13, 2024, 11:05 | Insight
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology - JCO Oncology Practice
JCO Oncology Practice shared a post on X: "Guide to Understanding and Supporting International Medical Graduates…
Oct 13, 2024, 10:44 | Insight
Sharlene Gill: Duration of adjuvant treatment in Stage III colon cancer
Sharlene Gill shared a post on X: "Duration of adjuvant treatment in s3 colon cancer in…
Oct 11, 2024, 17:58 | Insight
Jarushka Naidoo: Randomized Phase II Trial Osimertinib with or without Ramucirumab in 1st line EGFR+NSCLC
Jarushka Naidoo shared a post on X: "RAMOSE: Randomized Ph II Trial Osimertinib+/-Ramucirumab in 1L EGFR+…
Oct 11, 2024, 17:21 | Insight
Xiuning Le: Phase 2 RAMOSE osimertinib with or without ramucrimab in 1L EGFR+ NSCLC
Xiuning Le shared a post on X: "Newly online Journal of Clinical Oncology. Our randomized phase…
Oct 9, 2024, 16:50 | Insight
Ghassan Abou-Alfa: ERBB2-altered gallbladder cancer characterization in Chile
Ghassan Abou-Alfa, Medical Oncologist, Memorial Sloan Kettering Cancer Center, shared a post on X: "Congratulations…
Oct 8, 2024, 15:41 | Insight
Elisa Agostinetto: Association between hormonal contraceptives and breast cancer risk in BRCA1 carriers
Elisa Agostinetto shared a post on X: “Out in Journal of Clinical Oncology: A pooled…
Oct 8, 2024, 10:16 | Blog
The Cancer Alliance call to ACT NOW for Close The Equity Gap to Leave No One Behind
Salome Meyer, Independent Consultant at Private, shared a post by Sharon Kapambwe, Technical Officer of…
Oct 3, 2024, 12:54 | Insight
Article of the Week, Suggested by the BPDCN International Registry
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the Week Suggested by the…
Sep 29, 2024, 18:45 | Insight
Ishwaria Subbiah: Understanding what goal concordant care truly means
Ishwaria Subbiah shared a post on LinkedIn: "Goal-Concordant Care Now out in Journal of Clinical Oncology …
Sep 27, 2024, 13:30 | Insight
Yüksel Ürün: Adjuvant nivolumab vs placebo in localized RCC patients at high recurrence risk post-nephrectomy by Robert J. Motzer
Yüksel Ürün shared a post on X: "CheckMate 914 (Part B) failed to show DFS improvement…
Sep 19, 2024, 14:33 | Insight
Prognostic Perception and Quality of Life in Patients with Metastatic Renal and Bladder Cancer
JCO Global Oncology shared a post on X: “Perceptions and Expectations: A Study on Prognostic…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 11, 2024, 16:34 | Insight
Andrea Necchi: Our next piece of the neoadjuvant puzzle in muscle-invasive bladder cancer
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post on X about…
Sep 2, 2024, 08:40 | Insight
Durable Responses to Atezolizumab Plus Bevacizumab in HCC
Saadvik Raghuramy shared a post on X about a recent paper by Ying-Chun Shen et…
Sep 2, 2024, 03:14 | Insight
Othman Al-Sawaf: Surrogacy of endpoints in 1L CLL trials
Othman Al-Sawaf, Haematologist and Medical Oncologist at the University Hospital Cologne, Cologne, Germany, shared a…
Sep 1, 2024, 20:21 | Blog
Andrea Necchi: MRI should be a routine for daily management of MIBC
Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared Nick James's, Professor of Prostate…
Aug 29, 2024, 03:06 | Blog
Mark Lewis: We’re accepting submissions for JCO Oncology Advances
Mark Lewis shared on X: "Calling all oncology researchers! We’re accepting submissions for JCO Oncology…
Aug 25, 2024, 14:15 | Insight
JCO Study Confirms Annual Mammograms Improve Breast Cancer Outcomes Across All Demographics
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn about a recent paper…
Aug 4, 2024, 23:39 | Insight
HERALD EPOC1806 study explores trastuzumab deruxtecan in solid tumors with HER2 amplification by ctDNA
Stephen Liu shared a post on X: "HERALD EPOC1806 study published in JCO explored trastuzumab…
Jul 28, 2024, 07:13 | Insight
William Schpero: There are long-standing disparities in clinical trial participation in the United States
William Schpero, assistant professor in the Division of Health Policy and Economics of the Department…
Jul 26, 2024, 00:16 | Insight
Impact of the intratumoral microbiome of NSCLC on outcomes with immunotherapy
Stephen Liu shared on X: "Impressive work on impact of the intratumoral microbiome of NSCLC…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 13, 2024, 22:16 | Insight
Erman Akkus: Management of cancer-related fatigue - ASCO guideline
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a…
Jul 6, 2024, 12:24 | Career
Omnia Korani: I have been accepted into the JCO Trainee Reviewer Mentoring Program
Omnia Korani, Assistant Lecturer at the National Cancer Institute, shared a post on LinkedIn: "Exciting…
Jul 5, 2024, 13:47 | Insight
Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO
Shilpa Gupta shared a post by Andrea Apolo, adding: "Huge congrats Andrea Apolo, leading this…
Jul 3, 2024, 22:59 | Blog
Aleix Prat: Our 2 articles published this week
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared on X:…
Jul 3, 2024, 14:37 | Insight
Jarushka Naidoo: Phase III RESILIENT Trial of Liposomal Irinotecan v Topotecan in 2L SCLC
Jarushka Naidoo shared a post on X: “Phase III RESILIENT Trial of Liposomal Irinotecan v…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 21, 2024, 14:36 | Insight
High ORR and low CRS rate with Linvoseltamab for R/R Multiple Myeloma
Recently Jeffrey Zonder shared a post on X about a recent paper by Naresh Bumma…
Jun 21, 2024, 10:50 | Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
May 16, 2024, 14:15 | Insight
Elie G. Dib: Excited to share the results of the TAPUR study
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital,…
May 12, 2024, 07:40 | Insight
Yüksel Ürün: Excellent research on plasma Kidney Injury Molecule-1
Yüksel Ürün shared on X: "Congratulations to Wenxin Xu and the team for their excellent…
May 12, 2024, 04:15 | Blog
Nico Gagelmann: Big achievement in JCO on timing of transplantation for patients with MDS
Nico Gagelmann, Chair of CAR-T for Plasma Cell Disorder Committee and Chair Trainee Committee at The…
May 9, 2024, 12:42 | Blog
Estela Rodriguez: So much work to do to address barriers and develop pragmatic trials
Estela Rodriguez shared on X: “Only 7.1% of patients with cancer participate in clinical trials- so…
Apr 19, 2024, 15:52 | Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Apr 8, 2024, 22:37 | Insight
Key Message Highlights from Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous…
Mar 28, 2024, 02:31 | Insight
Rami Manochakian: New Supportive Care Guideline by ASCO on Vaccination of adult with cancer
Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic, shared a post on X: "Hot off…
Mar 16, 2024, 10:45 | Drugs
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah recently shared a post on X/Twitter: “Exceptional Responses to Selpercatinib in RET Fusion–Driven…
Mar 3, 2024, 17:26 | Insight
Anjali Sibley: Let’s Harness the Healing Power - The Benefits of Exercise and Physical Activity During Cancer Treatment
Anjali Sibley, Clinical Associate Professor of Medicine at Stanford University School of Medicine, shared a…
Jan 29, 2024, 10:53 | Insight
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard…
Dec 12, 2023, 11:42 | Insight
Shruti Jolly: Treating lung cancer with immunotherapy and radiation without chemotherapy
Shruti Jolly, Associate Director for the Statewide Cancer Network at Michigan Medicine, shared on LinkedIn:…
May 28, 2023, 16:27 | Opinion
As an oncology community we still have a lot to do, that more and more children do not need to go into the palliative care clinic and get cured - Gevorg Tamamyan
Quoting Gevorg Tamamyan on LinkedIn, "When people ask me, isn't it difficult to work as…
All: 56 Posts: 1 - 100
Special Coverage